Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth

Area of Science:

• Oncology
• Vascular Biology
• Cancer Research

Background:

• Malignant gliomas are aggressive brain tumors with limited treatment options.
• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth.
• Angiopoietin-2 (Ang2) is an angiogenic regulator whose role in glioma development requires further investigation.

Purpose of the Study:

• To analyze tumor growth, vascularization, and angiopoietin-2 (Ang2) expression during U-87 MG xenograft development.
• To investigate the effect of sustained Ang2 expression on angiogenesis and tumor growth.
• To evaluate the therapeutic potential of sustained Ang2 expression in malignant gliomas.

Main Methods:

• U-87 MG human glioblastoma cells were implanted intracranially in mice to create xenografts.
• Tumor growth, vascularization, and Ang2 expression were analyzed at different time points.
• Angiogenesis was assessed using a chorioallantoic membrane chicken model.
• The effect of sustained Ang2 expression on xenograft development and animal survival was evaluated.

Main Results:

• Tumoral angiogenesis in U-87 MG xenografts followed a multistage process: avascular, prolific peripheral angiogenesis, and late vascular phases.
• Ang2 expression was observed in glioma cells and vascular structures, particularly at the tumor/brain interface and in peripheral vasculature.
• Sustained Ang2 expression impaired angiogenesis in the chicken model and led to tumor necrosis and vascular damage in xenografts.
• Animals with sustained Ang2 expression exhibited prolonged survival.

Conclusions:

• Deregulated Ang2 expression during gliomagenesis impedes successful tumor angiogenesis.
• Sustained Ang2 expression hinders vascular development and promotes tumor necrosis.
• Therapies designed to maintain Ang2 expression may represent a promising strategy for treating malignant gliomas.